{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1950"},{"groupId":"OG001","value":"1953"}],"units":"Participants"}],"description":"Cumulative incidence of breast-cancer-free interval events. BCFI events include local-regional recurrence, distant recurrence or contralateral breast cancer as a first event.","groups":[{"description":"Patients receive oral letrozole once daily for up to 5 years.\n\nLetrozole: Letrozole 2.5 mg taken orally once daily for 5 years","id":"OG000","title":"Group 2 Letrozole"},{"description":"Patients receive oral placebo once daily for up to 5 years.\n\nPlacebo: Placebo tablet taken orally once daily for 5 years","id":"OG001","title":"Group 1 Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"7 years","title":"Breast Cancer-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of patients"}